ProMIS Neurosciences Inc. (Nasdaq:PMN), a clinical-stage biotechnology firm specializing in treatments for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...

Investing.com -- ProMIS Neurosciences Inc (NASDAQ: PMN) stock surged 145% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead ...

Some commonalities between Alzheimer’s disease and other dementia and certain brain conditions like tumors and subdural ...

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease ...

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in ...

The rate at which our bodies age and wear down doesn't necessarily match our actual age, and the differences can help predict ...

NEW YORK, July 21, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hum ...

The Global Neurodegeneration Proteomics Consortium (GNPC) has published a series of research papers detailing their efforts ...

My husband recently received a $50,000 inheritance. We have no idea what to do with it. We want to be wise, but everything is ...

The much-loved broadcaster and her TV producer husband have written a book about her life in the public eye and what it's ...

Mayo Clinic Jacksonville supports a blood test for to diagnose Alzheimer's while Baptist Health implanted its first atrial leadless pacemaker.

STOCKHOLM, SE / ACCESS Newswire / July 21, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing ...